Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Leuprolide Acetate
MARCH 2024
Q2 2024 ASP Report
Aria analytics
Aria is dedicated to enhancing value for our members through cutting-edge analytics and business intelligence solutions. With this objective, our team has compiled a report to assist members in understanding the product landscape, visualizing ASP trends, and anticipating future ASPs for key products.
Our goal is to empower members with clear insights, enabling well-informed purchasing decisions and the development of sustainable, long-term strategies.
The
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
no
warranties regarding, the content, accuracy
completeness of the
the
property rights to any pharmaceutical product
content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes
representations nor
or
information presented. Aria GPO does not own
intellectual
mentioned herein.
Table of contents
• Product comparison
• Average Sales Prices Q1 2024 & Q2 2024
• Reimbursement information for Q2 2024
• Historical ASPs
• Average Change of ASP
• WAC vs. Initial ASPs
• ASP Percent Change from WAC
• Aria ASP predictive model
The content provided in this material is for informational purposes only and is not intended as legal advice or to replace a medical provider’s judgment. All information used in this material has been sourced from publicly available sources. Aria GPO “Aria” does not endorse or approve, assumes no responsibility for, and makes no representations nor warranties regarding, the content, accuracy or completeness of the information presented. Aria GPO does not own the intellectual property rights to any pharmaceutical product mentioned herein.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product comparison
Product Strength & Dosage Treatment Cold Chain
Lupron Depot1 (AbbVie)
Leuprolide Acetate Depot2 (Cipla)
Injection: Pre-filled syringe
3.75 mg, 22.5 mg, 30 mg, 45 mg
Treatment of advanced prostate cancer No
Injection: Pre-filled syringe
22.5 mg, 3-month kit
Eligard3 (Tolmar)
Injection: Single-dose kit
7.5 mg, 22.5 mg, 30 mg, 45 mg
Camcevi4 (Accord)
Injectable emulsion: Pre-filled syringe
42 mg
Palliative treatment of advanced prostate cancer Yes
Treatment of adult patients with advanced prostate cancer
1. Https://dailymed.Nlm.Nih.Gov/dailymed/druginfo.Cfm?Setid=00c486b0-bd7b-4898-834d-8c656e5e73cb
2. Https://dailymed.Nlm.Nih.Gov/dailymed/druginfo.Cfm?Setid=1563a30b-66e0-445d-ba3e-1ccd5218133f
3. Https://dailymed.Nlm.Nih.Gov/dailymed/druginfo.Cfm?Setid=b78d1919-9dee-44fa-90f9-e0a26d32481d
4. Https://dailymed.Nlm.Nih.Gov/dailymed/druginfo.Cfm?Setid=d7a8761a-d953-413a-e053-2a95a90a60ee
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product WAC Previous ASP New ASP % Change Avg % Change Lupron Depot (AbbVie) $6,132.27 $513.12 $525.46 2.40% -0.09% Eligard (Tolmar) $1,355.07 $513.12 $525.46 2.40% -0.09% Leuprolide Acetate Depot (Cipla) $1,355.07 $1,005.51 $796.90 -20.75% -12.51% Camcevi (Accord) $4,145.70 $2,369.43 $2,407.23 1.60% -6.51% 2.40% 2.40% -20.75% 1.60% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 Lupron Depot (AbbVie) Eligard (Tolmar) Leuprolide Acetate Depot (Cipla) Camcevi (Accord)
Previous ASP New ASP
Average Sales Prices Q1 2024 & Q2 2024
ASP Change
*Includes Medicare sequestration
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Product Launch Date HCPCS WAC ASP Anticipated Medicare Reimbursement* Innovator Lupron Depot (AbbVie) 10/31/1990 J9217 $6,132.27 $525.46 $548.07 505(b)(2) Eligard (Tolmar) 12/01/2004 J9217 $1,355.07 $525.46 $548.07 Leuprolide Acetate (Cipla) 12/31/2022 J1954 $1,355.07 $796.90 $831.20 Camcevi (Accord) 4/30/2022 J1952 $4,145.70 $2,407.23 $2,510.84
Reimbursement information for Q1 2024
Historical ASPs
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Lupron Depot (AbbVie)
Eligard (Tolmar)
Leuprolide Acetate Depot (Cipla) Camcevi (Accord)
Average Change of ASP
This graph showcases the cumulative average change in the average sales price (ASP) for the Leuprolide Acetate family, tracking changes from the launch of biosimilars to each quarter's ASP. It highlights the evolution of ASP over the product's lifecycle and the fluctuating rate of change, providing a concise overview of pricing dynamics.
*Refers to the WAC when the first ASP was released
© 2024, Aria GPO and/or its affiliates. All
Copyright
rights reserved. Private and Confidential.
-20% -15% -10% -5% 0% 5% 10% 15% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024
Lupron Depot (AbbVie) Eligard (Tolmar)
Leuprolide Acetate Depot (Cipla) Camcevi (Accord)
WAC* vs. Initial ASPs
*Refers to the WAC when the first ASP was released
© 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
Copyright
-65.06% -47.13% -11.13% -9.83% -68.72% -52.66% -24.38% 0.00% -68.28% -51.99% -25.80% -20.44% $0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500
Lupron Depot (AbbVie)
Eligard (Tolmar)
Leuprolide Acetate Depot (Cipla)
Camcevi (Accord)
WAC First ASP Second ASP Third ASP
ASP Percent Change from WAC*
*Refers to the WAC when the first ASP was released
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
-100% -90% -80% -70% -60% -50% -40% -30% -20% -10% 0% Q1 2019 Q2 2019 Q3 2019 Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Q4 2021 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Lupron Depot
Eligard
Leuprolide Acetate Depot
Camcevi
(AbbVie)
(Tolmar)
(Cipla)
(Accord)
Aria ASP predictive model
In line with Aria's goal to provide key insights to our members, our analytics team has developed a proprietary predictive ASP model for the Leuprolide Acetate product family.
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential.
$0 $500 $1,000 $1,500 $2,000 $2,500 $3,000 $3,500 $4,000 $4,500 Q12019 Q22019 Q32019 Q42019 Q12020 Q22020 Q32020 Q42020 Q12021 Q22021 Q32021 Q42021 Q12022 Q22022 Q32022 Q42022 Q12023 Q22023 Q32023 Q42023 Q12024 Q22024Q32024Predicted
Eligard
Lupron Depot (AbbVie)
(Tolmar)
Leuprolide
Acetate Depot (Cipla) Camcevi (Accord)
Copyright © 2024, Aria GPO and/or its affiliates. All rights reserved. Private and Confidential. Thank you. www.ariagpo.com info@ariagpo.com